iBio, Inc. Files 8-K: Material Agreement & Disclosures
Ticker: IBIO · Form: 8-K · Filed: Aug 21, 2025 · CIK: 1420720
| Field | Detail |
|---|---|
| Company | Ibio, Inc. (IBIO) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $0.699, $0.70, $50 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, disclosure, financials
TL;DR
iBio signed a big deal, filed financials, and dropped some news. Keep an eye on this one.
AI Summary
On August 19, 2025, iBio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also made a Regulation FD disclosure and filed financial statements and exhibits. iBio, Inc. is incorporated in Delaware and its principal executive offices are located in San Diego, California.
Why It Matters
This 8-K filing indicates a significant event for iBio, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details warrants a medium risk assessment.
Key Players & Entities
- iBio, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (address) — Address of principal executive offices
- 001-35023 (company_id) — Commission File Number
- 26-2797813 (tax_id) — IRS Employer Identification No.
FAQ
What is the nature of the material definitive agreement entered into by iBio, Inc. on August 19, 2025?
The filing states that iBio, Inc. entered into a material definitive agreement on August 19, 2025, but the specific terms and nature of this agreement are not detailed in the provided text.
What other items are reported in this 8-K filing besides the material definitive agreement?
This 8-K filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits.
Where are iBio, Inc.'s principal executive offices located?
iBio, Inc.'s principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
In which state is iBio, Inc. incorporated?
iBio, Inc. is incorporated in Delaware.
What is the Commission File Number for iBio, Inc.?
The Commission File Number for iBio, Inc. is 001-35023.
Filing Stats: 1,958 words · 8 min read · ~7 pages · Grade level 12.8 · Accepted 2025-08-21 16:11:41
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq S
- $0.699 — nt and accompanying Series G Warrant is $0.699. Each Pre-Funded Warrant and the pre-f
- $0.70 — nd will have an exercise price equal to $0.70 per whole share of common stock (or $0.
- $50 million — fering are expected to be approximately $50 million before deducting underwriting discounts
Filing Documents
- tm2523907d1_8k.htm (8-K) — 41KB
- tm2523907d1_ex1-1.htm (EX-1.1) — 211KB
- tm2523907d1_ex4-1.htm (EX-4.1) — 95KB
- tm2523907d1_ex4-2.htm (EX-4.2) — 114KB
- tm2523907d1_ex4-3.htm (EX-4.3) — 107KB
- tm2523907d1_ex5-1.htm (EX-5.1) — 19KB
- tm2523907d1_ex99-1.htm (EX-99.1) — 10KB
- tm2523907d1_ex99-2.htm (EX-99.2) — 14KB
- tm2523907d1_ex5-1img001.jpg (GRAPHIC) — 4KB
- tm2523907d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-25-081419.txt ( ) — 941KB
- ibio-20250819.xsd (EX-101.SCH) — 3KB
- ibio-20250819_lab.xml (EX-101.LAB) — 33KB
- ibio-20250819_pre.xml (EX-101.PRE) — 22KB
- tm2523907d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 21, 2025 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: Chief Legal Counsel